PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PRIMARY OBJECTIVES: I. To establish the safety of anti-CSF1 monoclonal antibody PD-0360324 (PD 0360324) followed by cyclophosphamide in patients with epithelial ovarian, fallopian tube, and primary peritoneal cancers. II. To examine the density of CD8+ T cells in tumor biopsies before and after PD 0360324. SECONDARY OBJECTIVES: I. To evaluate response rate and progression free survival associated with low dose oral cyclophosphamide after PD 0360324 treatment. II. To evaluate M-CSF concentrations before and after treatment with PD 0360324 and during cyclophosphamide therapy. TERTIARY OBJECTIVES: I. To evaluate the immunologic effects of PD 0360324 on peripheral blood and ovarian cancer tissue. II. To explore the relationships between drug concentration and immunologic biomarkers and response. OUTLINE: Patients receive anti-CSF1 monoclonal antibody PD 0360324 intravenously (IV) over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide orally (PO) once daily (QD). Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 and 90 days.